Alginic acid (combination preparation)

Generic name
Alginic acid (combination preparation)
Brand name
ATC Code
A02BX13
Compare …

Alginic acid (combination preparation)

Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Pharmacokinetics in children

The mechanism of action of the drug is not dependent on absorption in the systemic circulation.

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Gastro-oesophageal reflux
  • Oral
    • Suspension for oral use
      • 1 year up to 10 years
        • 10 ml/dose, as required, max. 4 times daily.
        • Directions for administration:

          Take after a meal and before sleeping.

    • Chewing tablet
      • 10 years up to 18 years
        • 350 - 1.050 mg/dose, as required, max. 4x daily.
        • Directions for administration:

          Take after a meal and before sleeping.

      • 10 years up to 18 years
        [2] [3]
        • 350 - 1.050 mg/dose, as required, max. 4x daily.
        • Directions for administration:

          Take after a meal and before sleeping.

    • Powder for oral use
      • 1 month up to 2 years and ≥ 4.5 kg

        • 2 sachets per dose ( contains 225 mg sodium alginate and 87.5 mg magnesium alginate), max 12 sachets per 24 hours

      • Term neonate and < 4.5 kg

        • 1 sachet per dosis ( contains 225 mg sodium alginate and 87.5 mg magnesium alginate), max 6 sachets per 24 hours.

          Use only under medical supervison

           

Renal impaiment in children > 3 months

No information available on dose adjustment in renal impairment.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects

No information is present at this moment.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications in children

Gaviscon suspension and sachets are high in sodium. Not to be used in situations where excessive water loss is likely, e.g. fever, diarrhoea, vomiting or high room temperature. Not to be used in gastroenteritis where the appropriate treatment is rehydration with fluid replacement.Not to be used when treating infants with known or suspected impairment of renal function as the sodium content may add to the risk of hypernatraemia.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions in children

Children with enteritis, gastroenteritis or renal insufficiency have an increased risk of hypernatraemia.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

H2-receptor antagonists
A02BA01
A02BA03
A02BA02
Proton pump inhibitors
A02BC05
A02BC01
A02BC02
Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)
A02BX02

References

  1. Rademaker C.M.A. et al, Geneesmiddelen-Formularium voor Kinderen, 2007
  2. Reckitt Benckiser Healthcare (UK) Limited, SmPC Gaviscon (RVG 08401, 106364, 106116) 12-07-2021, www.geneesmiddeleninformatiebank.nl
  3. Nordic Drugs AB, SmPC Gaviscon (MARKEDSFØRINGSTILLATELSENUMMER 65359) 26.09.2016, www.legemiddelsok.no
  4. Reckitt Benckiser Healthcare (UK) Limited,, SmPC Gaviscon Infant (PL 00063/0099) 14-02-2020 (UK), www.medicines.org.uk/emc

Changes

Therapeutic Drug Monitoring


Overdose